CN111630187A - 鉴定结直肠癌状态的方法和试剂盒 - Google Patents
鉴定结直肠癌状态的方法和试剂盒 Download PDFInfo
- Publication number
- CN111630187A CN111630187A CN201880087486.3A CN201880087486A CN111630187A CN 111630187 A CN111630187 A CN 111630187A CN 201880087486 A CN201880087486 A CN 201880087486A CN 111630187 A CN111630187 A CN 111630187A
- Authority
- CN
- China
- Prior art keywords
- seq
- sequence
- sequence shown
- gene
- primer pair
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000001333 Colorectal Neoplasms Diseases 0.000 title claims abstract description 146
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 142
- 238000000034 method Methods 0.000 title claims abstract description 59
- 230000011987 methylation Effects 0.000 claims abstract description 165
- 238000007069 methylation reaction Methods 0.000 claims abstract description 165
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 150
- 239000000090 biomarker Substances 0.000 claims abstract description 93
- 239000012472 biological sample Substances 0.000 claims abstract description 86
- 101000995332 Homo sapiens Protein NDRG4 Proteins 0.000 claims abstract description 48
- 101150042012 SEPTIN9 gene Proteins 0.000 claims abstract description 48
- 102100026437 Branched-chain-amino-acid aminotransferase, cytosolic Human genes 0.000 claims abstract description 43
- 101000766268 Homo sapiens Branched-chain-amino-acid aminotransferase, cytosolic Proteins 0.000 claims abstract description 42
- 102100024504 Bone morphogenetic protein 3 Human genes 0.000 claims abstract description 41
- 101000762375 Homo sapiens Bone morphogenetic protein 3 Proteins 0.000 claims abstract description 41
- 102100026087 Syndecan-2 Human genes 0.000 claims abstract description 37
- 102100034432 Protein NDRG4 Human genes 0.000 claims abstract description 36
- 102000012060 Septin 9 Human genes 0.000 claims abstract description 36
- 102100037799 DNA-binding protein Ikaros Human genes 0.000 claims abstract description 35
- 101000599038 Homo sapiens DNA-binding protein Ikaros Proteins 0.000 claims abstract description 35
- 101000692109 Homo sapiens Syndecan-2 Proteins 0.000 claims abstract description 35
- 102100033798 Homeobox protein aristaless-like 4 Human genes 0.000 claims abstract 14
- 101000779608 Homo sapiens Homeobox protein aristaless-like 4 Proteins 0.000 claims abstract 14
- 101001108246 Homo sapiens Neuronal pentraxin-2 Proteins 0.000 claims abstract 8
- 101001132698 Homo sapiens Retinoic acid receptor beta Proteins 0.000 claims abstract 8
- 101000803403 Homo sapiens Vimentin Proteins 0.000 claims abstract 8
- 102100021878 Neuronal pentraxin-2 Human genes 0.000 claims abstract 8
- 102100033909 Retinoic acid receptor beta Human genes 0.000 claims abstract 8
- 102100035071 Vimentin Human genes 0.000 claims abstract 8
- 230000000903 blocking effect Effects 0.000 claims description 108
- 239000000523 sample Substances 0.000 claims description 102
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 96
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 94
- 229920001184 polypeptide Polymers 0.000 claims description 92
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 92
- 238000001514 detection method Methods 0.000 claims description 90
- 238000006243 chemical reaction Methods 0.000 claims description 76
- 238000012408 PCR amplification Methods 0.000 claims description 74
- 239000012634 fragment Substances 0.000 claims description 69
- 108020004414 DNA Proteins 0.000 claims description 67
- 238000011282 treatment Methods 0.000 claims description 31
- 206010028980 Neoplasm Diseases 0.000 claims description 30
- 150000007523 nucleic acids Chemical class 0.000 claims description 21
- 201000011510 cancer Diseases 0.000 claims description 20
- 239000003153 chemical reaction reagent Substances 0.000 claims description 18
- 238000007477 logistic regression Methods 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 17
- 108020004707 nucleic acids Proteins 0.000 claims description 17
- 101150008179 NPTX2 gene Proteins 0.000 claims description 14
- 101150010097 RARB gene Proteins 0.000 claims description 14
- 101150018417 VIM gene Proteins 0.000 claims description 14
- 239000002773 nucleotide Substances 0.000 claims description 14
- 125000003729 nucleotide group Chemical group 0.000 claims description 14
- 101150118392 sdc-2 gene Proteins 0.000 claims description 14
- 101150054887 ALX4 gene Proteins 0.000 claims description 13
- 230000003321 amplification Effects 0.000 claims description 13
- 101150016587 bcat-1 gene Proteins 0.000 claims description 13
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 13
- 210000002381 plasma Anatomy 0.000 claims description 13
- 101150016712 IKZF1 gene Proteins 0.000 claims description 12
- 101150006966 bmp3 gene Proteins 0.000 claims description 12
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 12
- 238000007400 DNA extraction Methods 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 10
- 101100218949 Rattus norvegicus Bmp3 gene Proteins 0.000 claims description 8
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical group [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- 208000009956 adenocarcinoma Diseases 0.000 claims description 7
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims description 7
- 201000010879 mucinous adenocarcinoma Diseases 0.000 claims description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 5
- 238000001574 biopsy Methods 0.000 claims description 5
- 230000000295 complement effect Effects 0.000 claims description 5
- 238000005259 measurement Methods 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 101150087690 ACTB gene Proteins 0.000 claims description 4
- 206010003445 Ascites Diseases 0.000 claims description 4
- 101001043970 Bacillus subtilis (strain 168) Branched-chain-amino-acid transaminase 1 Proteins 0.000 claims description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 4
- 210000002751 lymph Anatomy 0.000 claims description 4
- 238000012545 processing Methods 0.000 claims description 4
- 238000010791 quenching Methods 0.000 claims description 4
- 230000000171 quenching effect Effects 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 3
- 238000011191 terminal modification Methods 0.000 claims description 3
- 238000010923 batch production Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 24
- 239000011324 bead Substances 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 239000003550 marker Substances 0.000 description 19
- 201000010099 disease Diseases 0.000 description 17
- 239000011534 wash buffer Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000035945 sensitivity Effects 0.000 description 12
- 239000006174 pH buffer Substances 0.000 description 11
- 239000006148 magnetic separator Substances 0.000 description 10
- 239000007853 buffer solution Substances 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 229940122426 Nuclease inhibitor Drugs 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 239000003398 denaturant Substances 0.000 description 8
- 230000007067 DNA methylation Effects 0.000 description 6
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 6
- 239000003599 detergent Substances 0.000 description 6
- 239000012149 elution buffer Substances 0.000 description 6
- -1 BHQ3 Chemical compound 0.000 description 5
- 239000012148 binding buffer Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000012139 lysis buffer Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000010414 supernatant solution Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108091029523 CpG island Proteins 0.000 description 3
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000013399 early diagnosis Methods 0.000 description 3
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000009099 neoadjuvant therapy Methods 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- AOSFMYBATFLTAQ-UHFFFAOYSA-N 1-amino-3-(benzimidazol-1-yl)propan-2-ol Chemical compound C1=CC=C2N(CC(O)CN)C=NC2=C1 AOSFMYBATFLTAQ-UHFFFAOYSA-N 0.000 description 1
- BRRSNXCXLSVPFC-UHFFFAOYSA-N 2,3,4-Trihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1O BRRSNXCXLSVPFC-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- UDGUGZTYGWUUSG-UHFFFAOYSA-N 4-[4-[[2,5-dimethoxy-4-[(4-nitrophenyl)diazenyl]phenyl]diazenyl]-n-methylanilino]butanoic acid Chemical compound COC=1C=C(N=NC=2C=CC(=CC=2)N(C)CCCC(O)=O)C(OC)=CC=1N=NC1=CC=C([N+]([O-])=O)C=C1 UDGUGZTYGWUUSG-UHFFFAOYSA-N 0.000 description 1
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 1
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 description 1
- 101710142286 Branched-chain-amino-acid transaminase 1 Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 230000026641 DNA hypermethylation Effects 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- PQUCIEFHOVEZAU-UHFFFAOYSA-N Diammonium sulfite Chemical compound [NH4+].[NH4+].[O-]S([O-])=O PQUCIEFHOVEZAU-UHFFFAOYSA-N 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000883798 Homo sapiens Probable ATP-dependent RNA helicase DDX53 Proteins 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- 208000009184 Neoplasms by Histologic Type Diseases 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 102100038236 Probable ATP-dependent RNA helicase DDX53 Human genes 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013398 bayesian method Methods 0.000 description 1
- 238000001369 bisulfite sequencing Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000007847 digital PCR Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000014200 hypermethylation of CpG island Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000007855 methylation-specific PCR Methods 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 208000022131 polyp of large intestine Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 150000005430 trihydroxybenzoic acid derivatives Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2523/00—Reactions characterised by treatment of reaction samples
- C12Q2523/10—Characterised by chemical treatment
- C12Q2523/125—Bisulfite(s)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
提供了一种在受试者中鉴定结直肠癌状态的方法,包括:1)从所述受试者采集生物样品;2)检测所述生物样品中生物标志物基因的甲基化水平,其中所述生物标志物基因选自如下基因的一种或多种:ALX4、BCAT1、BMP3、IKZF1、NDRG4、NPTX2、RARB、SDC2、Septin9和VIM;以及3)将步骤2)检测的甲基化水平与群体中相应生物标志物基因的正常甲基化水平进行比较,以确定所述受试者中的结直肠癌状态。还提供了用于鉴定受试者中结直肠癌状态的试剂盒。
Description
PCT国内申请,说明书已公开。
Claims (34)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2018/073821 WO2019144277A1 (zh) | 2018-01-23 | 2018-01-23 | 鉴定结直肠癌状态的方法和试剂盒 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111630187A true CN111630187A (zh) | 2020-09-04 |
Family
ID=67395234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880087486.3A Pending CN111630187A (zh) | 2018-01-23 | 2018-01-23 | 鉴定结直肠癌状态的方法和试剂盒 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20210032703A1 (zh) |
EP (1) | EP3792362A4 (zh) |
CN (1) | CN111630187A (zh) |
WO (1) | WO2019144277A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113249477A (zh) * | 2021-05-19 | 2021-08-13 | 北京艾克伦医疗科技有限公司 | 结直肠癌早期诊断的方法和试剂盒 |
CN116482367A (zh) * | 2023-05-04 | 2023-07-25 | 中国中医科学院望京医院(中国中医科学院骨伤科研究所) | 一种联合mSEPT9检测和生物标志物的结直肠癌检测方法 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230242990A1 (en) * | 2019-10-16 | 2023-08-03 | Xiamen Sciendox Biological Technology Co., Ltd. | Primer set, reagent, and kit for methylation of specific regions of human colorectal cancer-related genes, and application of the kit |
CN114207153A (zh) * | 2020-03-20 | 2022-03-18 | 上海鹍远健康科技有限公司 | 筛查结直肠瘤的方法和试剂盒 |
CN112159844B (zh) * | 2020-05-25 | 2022-05-03 | 浙江中创生物医药有限公司 | 结直肠癌dna甲基化的检测方法及试剂 |
CN111748636B (zh) * | 2020-08-31 | 2020-11-17 | 圣湘生物科技股份有限公司 | 辅助诊断结直肠癌的组合物、试剂盒及其用途 |
GB2620255A (en) * | 2022-05-09 | 2024-01-03 | Oxford Simcell Ltd | Method |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011126768A2 (en) * | 2010-03-29 | 2011-10-13 | Mayo Foundation For Medical Education And Research | Methods and materials for detecting colorectal cancer and adenoma |
CN106574303A (zh) * | 2014-06-04 | 2017-04-19 | 奎斯特诊断投资股份有限公司 | 用于结肠直肠癌的甲基化的标志物 |
CN106893777A (zh) * | 2017-03-02 | 2017-06-27 | 武汉艾米森生命科技有限公司 | 用于检测结直肠癌相关基因多位点甲基化试剂盒及应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2630669C1 (ru) * | 2016-07-21 | 2017-09-11 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") | Способ определения метилирования сайтов PuCGPy регуляторных областей генов-онкомаркеров колоректального рака методом GLAD-ПЦР-анализа и набор олигонуклеотидных праймеров и флуоресцентно-меченых зондов для осуществления указанного способа |
WO2018087129A1 (en) * | 2016-11-08 | 2018-05-17 | Region Nordjylland, Aalborg University Hospital | Colorectal cancer methylation markers |
-
2018
- 2018-01-23 CN CN201880087486.3A patent/CN111630187A/zh active Pending
- 2018-01-23 US US16/964,154 patent/US20210032703A1/en not_active Abandoned
- 2018-01-23 EP EP18902067.0A patent/EP3792362A4/en active Pending
- 2018-01-23 WO PCT/CN2018/073821 patent/WO2019144277A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011126768A2 (en) * | 2010-03-29 | 2011-10-13 | Mayo Foundation For Medical Education And Research | Methods and materials for detecting colorectal cancer and adenoma |
CN106574303A (zh) * | 2014-06-04 | 2017-04-19 | 奎斯特诊断投资股份有限公司 | 用于结肠直肠癌的甲基化的标志物 |
CN106893777A (zh) * | 2017-03-02 | 2017-06-27 | 武汉艾米森生命科技有限公司 | 用于检测结直肠癌相关基因多位点甲基化试剂盒及应用 |
Non-Patent Citations (3)
Title |
---|
RASMUSSEN SL.等: "Hypermethylated DNA, a circulating biomarker for colorectal canc", 《PLOS ONE》 * |
RASMUSSEN SL.等: "Hypermethylated DNA, a circulating biomarker for colorectal cancer detection", 《PLOS ONE》 * |
YOUNG GP.等: "A cross-sectional study comparing a blood test for methylated BCAT1 and IKZF1 tumor-derived DNA with CEA for detection of recurrent colorectal cancer", 《CANCER MED.》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113249477A (zh) * | 2021-05-19 | 2021-08-13 | 北京艾克伦医疗科技有限公司 | 结直肠癌早期诊断的方法和试剂盒 |
CN116482367A (zh) * | 2023-05-04 | 2023-07-25 | 中国中医科学院望京医院(中国中医科学院骨伤科研究所) | 一种联合mSEPT9检测和生物标志物的结直肠癌检测方法 |
Also Published As
Publication number | Publication date |
---|---|
EP3792362A4 (en) | 2021-11-17 |
EP3792362A8 (en) | 2021-05-12 |
WO2019144277A1 (zh) | 2019-08-01 |
EP3792362A1 (en) | 2021-03-17 |
US20210032703A1 (en) | 2021-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112567049A (zh) | 鉴定胃癌状态的方法和试剂盒 | |
CN111630187A (zh) | 鉴定结直肠癌状态的方法和试剂盒 | |
Resnick et al. | Current and emerging trends in Lynch syndrome identification in women with endometrial cancer | |
CN111630186A (zh) | 鉴定肺癌状态的方法和试剂盒 | |
CN109022567A (zh) | 用于鉴定肺结节和/或肺癌状态的试剂盒及其应用 | |
CN113249477A (zh) | 结直肠癌早期诊断的方法和试剂盒 | |
WO2016115354A1 (en) | Methods for cancer diagnosis and prognosis | |
CN113785076A (zh) | 预测癌症预后的方法及其组合物 | |
KR102067607B1 (ko) | Y 염색체 메틸화 사이트의 전립선암 진단 마커로써의 응용 | |
US20090192045A1 (en) | Molecular staging of stage ii and iii colon cancer and prognosis | |
CN108977544A (zh) | 用于鉴定胃癌和/或胃息肉的试剂盒及其应用 | |
CN109082467A (zh) | 用于鉴定乳腺癌状态或乳腺癌前病变的试剂盒及其应用 | |
KR102546357B1 (ko) | 인간 포스포다이에스테라제 4d 변이체 7 발현에 기초한 위험 점수 | |
US20150037804A1 (en) | 3.4 kb mitochondrial dna deletion for use in the detection of cancer | |
CN113234821B (zh) | 鉴定食管癌状态的方法和试剂盒 | |
CN113234820A (zh) | 鉴定前列腺癌状态的方法和试剂盒 | |
JP2013542733A (ja) | 結腸直腸癌のスクリーニング方法 | |
CN113897434A (zh) | 鉴定肝癌状态的方法和试剂盒 | |
CN113278692A (zh) | 鉴定肺结节状态的方法和试剂盒 | |
CN114438208A (zh) | 通过外泌体miRNA生物标志物进行肺癌诊断的检测试剂盒和方法 | |
JP5009289B2 (ja) | Maltリンパ腫の検査方法及びキット | |
CN113186282B (zh) | 鉴定胰腺癌状态的方法和试剂盒 | |
CN112585282A (zh) | 鉴定乳腺癌状态的方法和试剂盒 | |
US12018333B2 (en) | Method and kit for identifying lung cancer status | |
JP6103866B2 (ja) | 大腸ガン検出方法、診断用キット及びdnaチップ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200904 |
|
RJ01 | Rejection of invention patent application after publication |